FINANCIAL TRUST COMPANY INC ACCT. For the Period 4/1/12 to 4/30/12 Note P indicates position adjusted for Pending Trade Activity. Unrealized GainiLoss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional information. Equity Detail Price Quality Value Adjusted Tax Cost Unrealized Gain/Loss Est. Annual Inc Original Cost Accrued Div. Yield US Large Cap Equity ARIAD PHARMACEUTICALS INC 18.30 16,535.000 289,520.50 251,475.52 18,044.58 04033A-10-0 ARIA BIDDEN IDEC INC 134.01 2.095 000 280 750 95 250,454.95 30,296.00 09062X-10-3 BIIB DB CONT BUFF EQ MS 08/07/12 81.37 1,000000.000 813,700.00 1,000,000.00 (188,300.00) 25% CONTIN BARRIER- 13%CPN 30% CAP INITIAL LEVEL-0715111 MS.21.09 2515A1-A7-6 HSBC MARKET PLUS SPX 05/17113 101.67 5,000,000.000 5,083,500.00 5,000,000.00 83,500.00 72% KO BARRIER- 0%CPN ,UNCAPPED INITIAL LEVEL-02/14/12 SPX:1350.50 4042K1-XQ-1 SO MARKET PLUS SPX 02107/13 108.93 2,000,000.000 2.178,600 00 2,000,000 00 178,600.00 75% CONTIN BARRIER- 8.25%CPN ,UNCAPPED INITIAL LEVEL-08/03/11 SPX:1.260.34 78423A-2Y-7 Total US Large Cap Equity $8.626.071.45 $8.501.930.47 3124.140.98 S0.00 0.00% JP Morgan Acco LI nt M Page 5 of 26 Consolidated Statement Page 8 Confidential Treatment Requested by JPMorgan Chase CONFIDENTIAL JPM-SDNY-000 15786 SDNY_GM_00284984 EFTA01492965